Moderna Inc.
Moderna Approves One-Time Stock Option Exchange Program
Summary
On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where the stockholders approved a one-time stock option exchange program for non-Executive Committee employees by a vote of 231,049,158 For, 6,167,159 Against, and 250,409 Abstain. Additionally, they approved the adjournment of the meeting if necessary by a vote of 223,991,059 For, 13,198,386 Against, and 277,281 Abstain. No broker non-votes were recorded.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement